Monday, 18 March 2013

BrainStorm to commence Phase 2 clinical trials for Amyotrophic lateral sclerosis

BrainStorm Cell Therapeutics announced yesterday its agreement with the Mayo Clinic to commence a Phase 2 clinical trial for Amyotrophic lateral sclerosis( Lou Gehrig's Disease). Purpose of the study is to assess the safety and efficacy of Nurown, a mesenchymal stem cell based therapy that produces neural cells.

BrainStorm says that their Phase I findings indicate that the treatment is promising, with ALS patients experiencing a "positive clinical outcome"  after receiving the NurOwn therapy. Anthony Windebank has been appointed as principal investigator of the study.

BrainStorm aims to enrol patients into clinical trials in the following clinics:
  • Mayo Clinic
  • University of Massachusetts
  • Massachusetts General a

"This is another step forward in finding a potentially effective treatment option for those patients with ALS," said BrainStorm CEO Alon Natanson.

MRI of an ALS patient
MRI of an ALS patient

The findings of the Phase 1 trial will be presented during the annual meeting of the American Academy of Neurology, scheduled for March 20.


BrainStorm Cell Therapeutics is a biotechnology company based in Israel, developing autologous stem cell-based therapies for various neurodegenerative diseases including:
  • Amyotrophic Lateral Sclerosis 
  • Multiple Sclerosis 
  • Parkinson’s Disease (PD)
You can read more about NurOwn here



No comments:

Post a Comment

Please note that we dont offer any kind of medical advice. Questions requesting specific medical advice (e.g. where can I get this treatment, will this cure XXX condition, etc) will be published but most probably ignored by the administrators. :)

Note to spammers: You shall not pass. If you really want a link from us then consider making a stem cell related guest post !